A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 721 participants.
Also called NCT02030600
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 721 participants
- Sponsor
- Registry
-
NCT02030600
-
- Main results
- Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial
- Other papers using this trial's data
- Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02030600. Randomized; double masking; primary purpose treatment. Start 2014-01-06 (actual); primary completion 2015-12-04 (actual). Results posted on 2017-01-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes
- Acronym
- SWITCH 2
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02030600- Content hash
e3943673c67e13d458ba98ec71672ae33d3f16dc8374cd6a13b6f96cc31ccf87